文献速递免疫规划传染病防控与疫情报告

孟加拉国5岁以下儿童在单剂口服霍乱疫苗初次接种超过三年后加强接种的免疫应答增强

Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5 years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccine.
PubMed 文献 · Vaccine · 2019-12-24

研究纳入240名曾接受单剂口服霍乱疫苗的参与者,在初次接种超过3年后加强接种,比较加强组与安慰剂对照组的免疫应答。结果显示各年龄组加强组和对照组在接种后均有杀弧菌抗体应答,5岁以下加强组对脂多糖的杀弧菌抗体应答显著高于对照组。作者认为单剂加强可在曾接种人群中产生免疫应答,但需进一步研究评估不同策略的保护效果及最佳间隔。

要点

  • 5岁以下加强组接种首剂后两周对脂多糖的杀弧菌抗体应答显著高于对照组。
  • 各年龄组加强组和对照组在接种后均对霍乱弧菌O1和O139产生杀弧菌抗体应答。
  • 作者认为需进一步研究评估不同策略的保护效果及初次与加强接种的最佳间隔。

核心结论

  • 单剂加强接种可在曾接种口服霍乱疫苗的人群中产生免疫应答,5岁以下儿童加强后免疫应答较对照组增强。

研究设计与样本

  • 研究纳入240名曾接受单剂口服霍乱疫苗的参与者,于2017年3月至9月间入组,距初次接种超过3年,比较加强组与安慰剂对照组的免疫应答。
  • 参与者分为4至<5岁、5至<18岁和>18岁三个年龄组,在接种前及接种第1剂和第2剂后采集血液。

主要发现

  • 各年龄组加强组和对照组在接种第1剂和第2剂后均对霍乱弧菌O1和O139产生杀弧菌抗体应答。
  • 5岁以下加强组接种首剂后两周对脂多糖的杀弧菌抗体应答显著高于对照组。
  • 5岁以下加强组接种首剂后对脂多糖的血浆IgA应答高于对照组。
  • 加强组粪便提取物黏膜抗体应答的升高与杀弧菌抗体和脂多糖应答相似。

临床怎么用

  • 作者认为单剂加强接种可在曾接种口服霍乱疫苗的人群中产生免疫应答。
  • 作者建议需进一步研究评估不同策略的保护效果,尤其针对5岁以下儿童,并确定所需的初次和加强剂量数。
  • 作者指出需更多关于初次与加强接种最佳间隔的信息以规划未来霍乱控制干预。

局限性

  • 作者指出需进一步研究评估不同策略的保护效果,尤其针对5岁以下儿童,并确定所需的初次和加强剂量数。
  • 作者指出需更多关于初次与加强接种最佳间隔的信息以规划未来霍乱控制干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We have earlier reported that a single dose of oral cholera vaccine (OCV) is protective in adults and children ≥5 years of age and sustained for 2 years. We enrolled participants (n = 240) from this study, between March-September 2017, over 3 years after receiving a primary single dose. Immune responses were measured in placebo group (Primary Immunization group: PI) and compared with those who received a single dose (Booster Immunization group: BI). The children were 4 to <5 years, 5 to <18 years and adults >18 years. Blood was collected at day 0 (before vaccination) and after receiving 1st and 2nd doses of OCV. Overall, the BI and PI groups showed vibriocidal antibody response after 1st and 2nd dose of vaccination in all age groups to V. cholerae O1 and O139. Young children in the BI group showed significantly higher vibriocidal antibody response two weeks after receiving the first dose as compared to PI group to LPS. Elevated plasma IgA responses to LPS after the first dose were observed among the BI group compared to the PI group among the young children. Mucosal antibody responses measured in fecal extracts showed similar increases as that of vibriocidal and LPS responses in the BI group. These results suggest a single boosting dose of OCV generated immune response in primed population >5 years of age who had earlier received OCV. However, young children who had received OCV earlier, boosting after a single dose, resulted in increased immune responses compared to the PI group. Further studies are needed to assess protection obtained from different strategies, especially for young children and to determine the numbers of primary and booster doses needed. In addition, more information is needed regarding the optimum interval between primary and booster doses to plan future interventions for cholera control. ClinicalTrials.gov Identifier: NCT02027207.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Chowdhury F, Bhuiyan TR, Akter A, et al. Augmented immune responses to a booster dose of oral cholera vaccine in Bangladeshi children less than 5 years of age: Revaccination after an interval of over three years of primary vaccination with a single dose of vaccine. Vaccine. 2019. PMID: 31879124. doi:10.1016/j.vaccine.2019.12.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。